Measurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA
By onMeasurement of GLP-1 release in cell supernatant from Hutu-80 enteroendocrine cells via ELISA
Structural basis for the specificity of PPM1H phosphatase for Rab GTPases
By onRaw data associated with DOI: 10.15252/embr.202152675
pCAG-OSF-ATG13 (2-197)-L151D
By onPlasmid for expression of human ATG13 HORMA L151D mutant in mammalian cells.
LC3-lipidation-assay
By onProtocol for an in vitro LC3 lipidation assay using purified proteins and synthetic liposomes.
Bile acids and neurological disease
By onThis review will focus on how bile acids are being used in clinical trials to treat neurological diseases due to their central involvement with the gut-liver-brain axis and their physiological and pathophysiological roles in both normal brain function and multiple neurological diseases. The synthesis of primary and secondary bile acids species and how the regulation of the bile acid pool may differ between the gut and brain is discussed. The expression of several bile acid receptors in brain and their currently known functions along with the tools available to manipulate them pharmacologically are examined, together with discussion of the interaction of bile acids with the gut microbiome and their lesser-known effects upon brain glucose and lipid metabolism. How dysregulation of the gut microbiome, aging and sex differences may lead to disruption of bile acid signalling and possible causal roles in a number of neurological disorders are also considered. Finally, we discuss how pharmacological treatments targeting bile acid receptors are currently being tested in an array of clinical trials for several different neurodegenerative diseases
Mass spectrometry proteomic data supporting the PPM1H/Rab8A crosslinking study described in doi: 10.15252/embr.202152675
By onRaw data associated with DOI: 10.15252/embr.202152675
Western blot – alpha-synuclein
By onThis protocol describes how to detect alpha-synuclein in protein derived from STC-1 cells by western blot using DAB/peroxidase or ECL to visualize the bands.
Hippocampal Neuronal Culture
By onThis protocol describes the procedure for hippocampal neuronal cultures from new - born mouse pups.
Creating pooled CRISPR-Cas9 knock-outs in NIH-3T3 cells
By onTo validate a genome wide CRISPR screen, the authors select the top hits and create lentiviruses to validate the hits.
Protocols for “Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice”.
By onThis is a collection of protocols associated to the manuscript "Characterizing the diversity of enteric neurons using Dopamine Transporter (DAT)-Cre reporter mice".
Sample Collection and Processing for RNA Analysis
By onThis protocol delineates the steps taken to collect frozen postmortem human brain samples and process them for RNA extraction and analysis.
Single-molecule Immunofluorescence Tissue Staining Protocol for Oligomer Imaging V.3
By onThis protocol details background fluorescence quenching and immunofluorescence staining of human brain tissue for oligomer imaging.
H9 ES AAVS1-NGN2 FAM134C-/-
By onES cells manipulated with CRISPR/Cas9 lack FAM134C receptor for ER-phagy. NEUROG2 construct introduced via AAVS1 locus in human embryonic stem cells, creating iNeurons. Derived from blastocyst stage, female, Homo sapiens.
pU6-pegRNA-LRRK2-G2019S-3a
By onIt can be used to introduce LRRK2-G2019S mutation using prime editing.
The emerging role of LRRK2 in tauopathies
By onParkinson’s disease (PD) is conventionally described as an α-synuclein aggregation disorder, defined by Lewy bodies and neurites, and mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common autosomal dominant cause of PD. However, LRRK2 mutations may be associated with diverse pathologies in patients with Parkinson’s syndrome including tau pathology resembling progressive supranuclear palsy (PSP). The recent discovery that variation at the LRRK2 locus is associated with the progression of PSP highlights the potential importance of LRRK2 in tauopathies. Here, the authors review the emerging evidence and discuss the potential impact of LRRK2 dysfunction on tau aggregation, lysosomal function, and endocytosis and exocytosis.
Challenging Beam Test
By onThe challenging beam test is used to measure motor performance, coordination, and balance.
